Maze Therapeutics, Inc. (MAZE) Key Metrics
MAZE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.53B
- Enterprise value
- $1.21B
- P/E (TTM)
- —
- Forward P/E
- 8.5
- PEG ratio
- —
- Price / sales
- 76.5
- Price / book
- 3.4
- EV / EBITDA
- 6.1
- Dividend yield
- —
- Beta
- —
MAZE key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMAZE returns How much profit the business earns on the capital it uses.
MAZE per-share figures Results divided by the shares outstanding at year-end.
MAZE financial health Debt, liquidity and how easily interest is covered.
MAZE efficiency & capital use Working capital cycle and where the cash goes.
MAZE valuation history
MAZE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MAZE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MAZE price vs earnings per share
MAZE key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.78B | — | — | — |
| Enterprise value | $1.46B | — | — | — |
| Price / book | 5.0 | — | — | — |
| Earnings yield | −7.4% | — | — | — |
| Free cash flow yield | −6.3% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — |
| Share price at fiscal year-end | $41.43 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $3.82 | $0.00 | $0.00 |
| Earnings per share | −$3.05 | $1.19 | −$2.29 | −$2.63 |
| Operating cash flow per share | −$2.60 | $1.73 | −$1.98 | −$2.27 |
| Free cash flow per share | −$2.62 | $1.71 | −$1.99 | −$2.31 |
| Cash per share | $7.96 | $4.49 | $0.67 | $2.28 |
| Book value per share | $8.26 | $4.50 | $0.23 | $2.32 |
| Tangible book value per share | $8.26 | $4.50 | $0.23 | $2.32 |
| Capex per share | $0.02 | $0.03 | $0.01 | $0.04 |
| Debt per share | $0.54 | $0.61 | $1.13 | $0.73 |
| Shares outstanding | 43.0M | 43.8M | 43.8M | 43.8M |
| Change in shares outstanding | −1.9% | +0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −47.5% | 50.5% | −180.1% | −113.3% |
| Return on invested capital (ROIC) | −358.0% | 196.8% | −242.9% | −261.2% |
| Return on assets (ROA) | −41.1% | 33.5% | −90.7% | −76.6% |
| Return on tangible assets | −33.0% | 21.7% | −140.4% | −76.6% |
| Free cash flow margin | — | 44.7% | — | — |
| Income quality (OCF / net income) | — | 1.45 | — | — |
| Financial health | ||||
| Total debt | $23.3M | $26.6M | $49.6M | $32.1M |
| Cash & short-term investments | $341.9M | $196.8M | $29.2M | $99.9M |
| Net debt | −$318.6M | −$170.2M | $20.5M | −$67.9M |
| Debt / equity | 0.07 | 0.14 | 4.94 | 0.32 |
| Debt / assets | 0.06 | 0.11 | 0.69 | 0.21 |
| Net debt / EBITDA | — | −3.00 | — | — |
| Current ratio | 15.50 | 9.76 | 2.09 | 5.11 |
| Quick ratio | 15.50 | 9.76 | 2.09 | 5.11 |
| Working capital | $327.2M | $181.0M | $17.8M | $85.4M |
| Invested capital | $36.4M | $26.7M | $30.5M | $33.6M |
| Tangible asset value | $355.0M | $196.9M | $10.1M | $101.4M |
| Net current asset value | $307.6M | $158.0M | −$27.3M | $57.6M |
| Graham number | — | $10.98 | — | — |
| Graham net-net per share | $7.00 | $3.50 | −$0.74 | $1.17 |
| Capital allocation | ||||
| Share buybacks (net) | $0 | — | — | — |
| Capex / revenue | — | 0.7% | — | — |
| Capex / operating cash flow | — | 1.5% | — | — |
| Capex / depreciation | 0.33 | 0.35 | 0.11 | 0.51 |
| Stock-based compensation / revenue | — | 5.8% | — | — |
| R&D / revenue | — | 49.8% | — | — |
| SG&A / revenue | — | 15.8% | — | — |
| Efficiency | ||||
| Days payables outstanding | 283.5 | 219.1 | 160.9 | 151.4 |
| Receivables turnover | 0.00 | — | — | — |
| Payables turnover | 1.29 | 1.67 | 2.27 | 2.41 |
| Asset turnover | 0.00 | 1.07 | 0.00 | 0.00 |
| Average receivables | $1.5M | — | — | — |
| Average payables | $1.9M | $2.0M | $1.8M | $1.6M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MAZE's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MAZE valuation and financial ratios
Maze Therapeutics earned a return on equity of −47.5% and a return on invested capital of −358.0% in fiscal 2025. It ended the year with $23.3 million of debt and $341.9 million in cash and short-term investments, a net cash position of $318.6 million.
See the MAZE income statement, the MAZE chart for price history, or the MAZE stock overview for the latest quote and news.
MAZE key metrics FAQ
What is Maze Therapeutics's return on equity?
Maze Therapeutics's return on equity (ROE) was −47.5% in fiscal 2025: net income of -$131.1 million on average shareholders' equity of $275.9 million.
What is Maze Therapeutics's ROIC?
Maze Therapeutics's return on invested capital was −358.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Maze Therapeutics have?
Maze Therapeutics had total debt of $23.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
What is Maze Therapeutics's free cash flow yield?
Maze Therapeutics generated -$112.7 million of free cash flow in fiscal 2025, a free cash flow yield of −6.3% on its market value at year-end ($1.8 billion).
What is Maze Therapeutics's current ratio?
Maze Therapeutics's current ratio was 15.50 at the end of fiscal 2025: current assets were 15.50 times current liabilities.